Why Geron Corporation’s (GERN) Stock Is Up 5.28%
As of Monday, July 27, Geron Corporation’s GERN share price has surged by 5.28%, which has investors questioning if this is right time to sell.Michael Rose
A+ Stock Grade Summary:
| VALUE: |
|
|
| GROWTH: |
|
|
| MOMENTUM: |
|
|
| EPS REVISIONS: |
|
|
| QUALITY: |
|
|
COMPANY SUMMARY
Geron Corporation, a commercial-stage biopharmaceutical company, focuses on the development of therapeutics products for oncology. The company’s product pipeline includes RYTELO, a telomerase inhibitor for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes with transfusion-dependent anemia; IMerge which is in Phase 3 clinical trial for the treatment of lower-risk myelodysplastic syndromes; IMpactMF that is in Phase 3 for the treatment of relapsed/refractory myelofibrosis; Impress which is in Phase 2 clinical trial to treat higher risk myelodysplastic syndromes and acute myeloid leukemia (AML); IMproveMF which is in Phase 1 clinical trial for the treatment of frontline myelofibrosis; and IMAGINE which is in phase 1/2 clinical trial for the treatment of relapsed/refractory AML. Geron Corporation was incorporated in 1990 and is headquartered in Foster City, California.
Commentary & Analysis
Why Geron Corporation’s (GERN) Stock Is Up 5.51%
As of Monday, July 06, Geron Corporation’s GERN share price has surged by 5.51%, which has investors questioning if this is right time to sell.Michael Rose
Why Geron Corporation’s (GERN) Stock Is Up 5.78%
As of Thursday, June 25, Geron Corporation’s GERN share price has surged by 5.78%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Geron Corporation’s (GERN) Stock Is Up 6.30%
As of Wednesday, June 24, Geron Corporation’s GERN share price has surged by 6.30%, which has investors questioning if this is right time to sell.Jenna Brashear
Why Geron Corporation’s (GERN) Stock Is Up 7.14%
As of Monday, June 22, Geron Corporation’s GERN share price has surged by 7.14%, which has investors questioning if this is right time to sell.Jenna Brashear
Financial Summary
| Share Statistics | GERN | Industry Median |
Percentile (All Stocks) |
|
| Market Cap (Mil) | $827.6 | $252.6 | 43% |
|
| Shares Out (Mil) | 669.4 | 52.3 | 91% |
|
| Institutional Ownership | 99.9% | 92.1% | 96% |
|
| Float (Mil) | 535.7 | 40.2 | 86% |
|
| Beta | 0.68 | 0.95 | 39% |
|
| Avg Daily Volume (000s) | 8,228 | 455 | 95% |
|
| Price Change (52-week) |
17.3% | 52.9% | 59% |
|
| Growth | GERN | Industry Median |
Percentile (All Stocks) |
|
| Sales (5yr) | 261.0% | 13.6% | 100% |
|
| Net Income (5yr) | (2.0%) | (9.9%) | 37% |
|
| EPS (5yr) | 14.8% | 16.0% | 55 |
|
| Dividends (5yr) | 0.0% | 0.0% | 0% |
|
| Cash Flow (5yr) | 14.9% | (15.6%) | 72% |
|
| Estimates | Qtrly | Current Fiscal Year |
Next Fiscal Year |
|
| # of Estimates | 2 | 2 | 2 | |
| Current EPS | ($0.010) | ($0.020) | $0.060 | |
| Month Ago EPS | ($0.010) | ($0.020) | $0.065 | |
| # Rev Up | 0 | 1 | 1 | |
| # Rev Down | 1 | 0 | 0 | |
| Three Months Ago EPS | ($0.010) | ($0.020) | $0.060 | |
| Year/Year Chg | 100.0% | (84.0%) | (228.0%) | |
| Financials | GERN | Industry Median |
Percentile (All Stocks) |
|
| Sales (TTM) (Mil) | $196 | $38 | 32% |
|
| Net Income (TTM) (Mil) | ($67) | ($43) | 14% |
|
| EPS (TTM) | ($0.101) | ($1.600) | 36% |
|
| Operating Cash Flow (TTM) (Mil) | ($126) | ($31) | 5% |
|
| Net Cash Flow (TTM) (Mil) | ($15) | $5 | 28% |
|
| Long-Term Debt (Q1) (Mil) | $121 | $5 | 46% |
|
| Enterprise Value (Q1) (Mil) | $591 | $180 | 36% |
|
| Valuation | GERN | Industry Median |
Percentile (All Stocks) |
|
| P/B | 3.58 | 2.56 | 70% |
|
| P/E | na | 19.0 | na |
|
| Dividend Yield | 0.0% | 0.0% | 0% |
|
| PEG (5yr hist) | na | 0.9 | na |
|
| Ratios | GERN | Industry Median |
Percentile (All Stocks) |
|
| Gross Margin | 61.0% | 63.8% | 74% |
|
| Net Margin | (34.3%) | (67.3%) | 14% |
|
| ROA | (12.3%) | (49.8%) | 24% |
|
| ROE | (27.1%) | (55.5%) | 21% |
|
| Liabilities to Assets | 57.1% | 30.3% | 50% |
|
| F-Score | 4 | 3 | 34% |
|
Geron Corporation did not pass any screens on 7/31/2026.
